Mark Lackner - Chief Scientific Officer at Zentalis Pharmaceuticals, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Scientific Officer
Stock Symbol
ZNTL on Nasdaq
Industry
Pharmaceutical Preparations
All Insider Reports
All Insider Reports

Mark Lackner - trading volume in the past year for Zentalis Pharmaceuticals, Inc.

Holdings reported by Mark Lackner for Zentalis Pharmaceuticals, Inc.

Class Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 196K $2.26M $11.54 Feb 2, 2024 Direct
Stock Option (Right to Buy) 141K Feb 1, 2024 Direct Common Stock

Transactions reported by Mark Lackner for Zentalis Pharmaceuticals, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.